

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36453 A3

(51) International Patent Classification⁷: **C07K 7/06**,
A61K 38/08

(21) International Application Number: PCT/US00/42010

(22) International Filing Date:
8 November 2000 (08.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/440,621 15 November 1999 (15.11.1999) US
09/514,036 25 February 2000 (25.02.2000) US
09/676,005 29 September 2000 (29.09.2000) US

CH-1066 Epalinges, Lausanne (CH). **CEROTTINI, Jean-Charles**; University of Lausanne, Ludwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges, Lausanne (CH). **ROMERO, Pedro**; University of Lausanne, Ludwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges, Lausanne (CH). **CERUNDOLO, Vincenzo**; John Radcliffe Hospital, Heddington, Oxford OX3 3DU (GB).

(74) Agent: **HANSON, Norman, D.**; Fulbright & Jaworski L.L.P., 666 Fifth Avenue, New York, NY 10103 (US).

(81) Designated States (*national*): AU, CA, CN, JP, KR.

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(71) Applicants: **LUDWIG INSTITUTE FOR CANCER RESEARCH** [CH/US]; 605 Third Avenue, New York, NY 10158 (US). **CHANCELLORS, MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD** [GB/GB]; University Offices, Wellington Square, Oxford OX1 2JD (GB).

Published:
— with international search report

(88) Date of publication of the international search report:
27 December 2001

(72) Inventors: **VALMORI, Danila**; University of Lausanne, Ludwig Institute for Cancer Research, Lausanne Branch,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NY-ESO-1 NANOPEPTIDE DERIVATIVES, AND USES THEREOF

(57) Abstract: The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.



WO 01/36453 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/42010

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K7/06 A61K38/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, STRAND, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JÄGER ET AL: "Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes" JOURNAL OF EXPERIMENTAL MEDICINE, JP, TOKYO, vol. 187, no. 2, 19 January 1998 (1998-01-19), pages 265-270, XP002096011 ISSN: 0022-1007 the whole document -----	1-38
A	WO 99 18206 A (US HEALTH ;WANG RONG FU (US); ROSENBERG STEVEN A (US)) 15 April 1999 (1999-04-15) the whole document -----	1-38

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 May 2001

Date of mailing of the international search report

25/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

G. Willière

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/42010

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9918206 A	15-04-1999	AU 9572098 A	27-04-1999
		EP 1021535 A	26-07-2000